This report is filed due to post-procedure access site bleeding.It was reported that on (b)(6) 2017, the patient had a previous mitral valve procedure.One mitraclip was implanted without reported issues.The mitral regurgitation was reduced from grade 4 to 2.On (b)(6) 2019, a baseline echocardiogram was performed and mitral regurgitation was observed grade 4+.Reportedly, the previously implanted mitraclip remained stable and well seated.There was no tissue or leaflet injury suspected.On (b)(6) 2019, two mitraclips were implanted, without a device issue, reducing the mr to grade 1+.Post-procedure, bleeding from the puncture site was observed along with low hemoglobin.As treatment, one unit of packed red blood cells was provided; manual compression was held for 1 hour and a new compression bandage was applied for 2 hours.Right femoral angiography performed on (b)(6) 2019 showed normal results.The event resolved without sequela.No additional information was provided regarding this issue.
|
Internal file number - (b)(4).There was no device malfunction and the device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of hemorrhage is listed in the mitraclip system instructions for use is a known possible complication associated with mitraclip procedures.Based on the information reviewed, the reported anemia and hemorrhage appear to be related to procedural conditions, and unrelated to the device since there was no reported device issue/malfunction during the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|